Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 26 entries
Sorted by: Best Match Show Resources per page
Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy.

Cancer management and research

Holt A, Khan MA, Gujja S, Govindarajan R.
PMID: 25565887
Cancer Manag Res. 2014 Dec 24;7:13-8. doi: 10.2147/CMAR.S74116. eCollection 2015.

BACKGROUND: Prostate cancer subjects with prostate-specific antigen (PSA) relapse who are treated with androgen deprivation therapy (ADT) are recommended to have baseline and serial bone densitometry and receive bisphosphonates. The purpose of this community population study was to assess...

Cite
Holt A, Khan MA, Gujja S, et al. Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy. Cancer Manag Res. 2014;7:13-8doi: 10.2147/CMAR.S74116.
Holt, A., Khan, M. A., Gujja, S., & Govindarajan, R. (2015). Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy. Cancer management and research, 713-8. https://doi.org/10.2147/CMAR.S74116
Holt, Abby, et al. "Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy." Cancer management and research vol. 7 (2015): 13-8. doi: https://doi.org/10.2147/CMAR.S74116
Holt A, Khan MA, Gujja S, Govindarajan R. Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy. Cancer Manag Res. 2014 Dec 24;7:13-8. doi: 10.2147/CMAR.S74116. eCollection 2015. PMID: 25565887; PMCID: PMC4284007.
Copy Download .nbib Format: NLM
Flutamide versus a cyproterone acetate-ethinyl estradiol combination in moderate acne: a pilot randomized clinical trial.

Clinical, cosmetic and investigational dermatology

Adalatkhah H, Pourfarzi F, Sadeghi-Bazargani H.
PMID: 21833162
Clin Cosmet Investig Dermatol. 2011;4:117-21. doi: 10.2147/CCID.S20543. Epub 2011 Jul 26.

BACKGROUND: The use of oral flutamide is rarely investigated in acne therapy. The aim of this study was to compare the efficacy of oral flutamide with that of a cyproterone-estradiol combination in treating acne lesions.METHODS: A randomized clinical trial...

Cite
Adalatkhah H, Pourfarzi F, Sadeghi-Bazargani H. Flutamide versus a cyproterone acetate-ethinyl estradiol combination in moderate acne: a pilot randomized clinical trial. Clin Cosmet Investig Dermatol. 2011;4:117-21doi: 10.2147/CCID.S20543.
Adalatkhah, H., Pourfarzi, F., & Sadeghi-Bazargani, H. (2011). Flutamide versus a cyproterone acetate-ethinyl estradiol combination in moderate acne: a pilot randomized clinical trial. Clinical, cosmetic and investigational dermatology, 4117-21. https://doi.org/10.2147/CCID.S20543
Adalatkhah, Hassan, et al. "Flutamide versus a cyproterone acetate-ethinyl estradiol combination in moderate acne: a pilot randomized clinical trial." Clinical, cosmetic and investigational dermatology vol. 4 (2011): 117-21. doi: https://doi.org/10.2147/CCID.S20543
Adalatkhah H, Pourfarzi F, Sadeghi-Bazargani H. Flutamide versus a cyproterone acetate-ethinyl estradiol combination in moderate acne: a pilot randomized clinical trial. Clin Cosmet Investig Dermatol. 2011;4:117-21. doi: 10.2147/CCID.S20543. Epub 2011 Jul 26. PMID: 21833162; PMCID: PMC3149479.
Copy Download .nbib Format: NLM
Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting.

Therapeutic advances in medical oncology

Puente J, Grande E, Medina A, Maroto P, Lainez N, Arranz JA.
PMID: 28529548
Ther Adv Med Oncol. 2017 May;9(5):307-318. doi: 10.1177/1758834017692779. Epub 2017 Mar 01.

The increasing knowledge of prostate cancer is leading to many questions about its natural history and to reconsider conventional therapeutic strategies. Androgen ablation therapy has been the standard therapy in the advanced setting. Although docetaxel has demonstrated increased survival...

Cite
Puente J, Grande E, Medina A, et al. Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting. Ther Adv Med Oncol. 2017;9(5):307-318doi: 10.1177/1758834017692779.
Puente, J., Grande, E., Medina, A., Maroto, P., Lainez, N., & Arranz, J. A. (2017). Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting. Therapeutic advances in medical oncology, 9(5), 307-318. https://doi.org/10.1177/1758834017692779
Puente, Javier, et al. "Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting." Therapeutic advances in medical oncology vol. 9,5 (2017): 307-318. doi: https://doi.org/10.1177/1758834017692779
Puente J, Grande E, Medina A, Maroto P, Lainez N, Arranz JA. Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting. Ther Adv Med Oncol. 2017 May;9(5):307-318. doi: 10.1177/1758834017692779. Epub 2017 Mar 01. PMID: 28529548; PMCID: PMC5424862.
Copy Download .nbib Format: NLM
The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy.

European urology

Hamilton RJ, Ding K, Crook JM, O'Callaghan CJ, Higano CS, Dearnaley DP, Horwitz EM, Goldenberg SL, Gospodarowicz MK, Klotz L.
PMID: 33390282
Eur Urol. 2021 Apr;79(4):446-452. doi: 10.1016/j.eururo.2020.12.031. Epub 2020 Dec 31.

BACKGROUND: Studies have conflicting results regarding the association between statin use and biochemical recurrence for prostate cancer (PCa). A limited number of studies examining statins in advanced stages report positive results, with a few specifically examining statins and androgen...

Cite
Hamilton RJ, Ding K, Crook JM, et al. The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. Eur Urol. 2020;79(4):446-452doi: 10.1016/j.eururo.2020.12.031.
Hamilton, R. J., Ding, K., Crook, J. M., O'Callaghan, C. J., Higano, C. S., Dearnaley, D. P., Horwitz, E. M., Goldenberg, S. L., Gospodarowicz, M. K., & Klotz, L. (2021). The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. European urology, 79(4), 446-452. https://doi.org/10.1016/j.eururo.2020.12.031
Hamilton, Robert J, et al. "The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy." European urology vol. 79,4 (2021): 446-452. doi: https://doi.org/10.1016/j.eururo.2020.12.031
Hamilton RJ, Ding K, Crook JM, O'Callaghan CJ, Higano CS, Dearnaley DP, Horwitz EM, Goldenberg SL, Gospodarowicz MK, Klotz L. The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. Eur Urol. 2021 Apr;79(4):446-452. doi: 10.1016/j.eururo.2020.12.031. Epub 2020 Dec 31. PMID: 33390282.
Copy Download .nbib Format: NLM
Primary androgen deprivation therapy for prostate cancer in koreans: a retrospective multicenter study.

The world journal of men's health

Seo WI, Kang PM, Kim TH, Moon KH, Chung JM, Lee DH, Kim IY, Min K, Chung J, Kim W, Kang DI.
PMID: 25606565
World J Mens Health. 2014 Dec;32(3):159-66. doi: 10.5534/wjmh.2014.32.3.159. Epub 2014 Dec 29.

PURPOSE: To evaluate the characteristics of patients who received primary androgen deprivation therapy (PADT) for prostate cancer and the clinical efficacy of this treatment.MATERIALS AND METHODS: Two hundred forty patients treated by PADT were reviewed. These patients could not...

Cite
Seo WI, Kang PM, Kim TH, et al. Primary androgen deprivation therapy for prostate cancer in koreans: a retrospective multicenter study. World J Mens Health. 2014;32(3):159-66doi: 10.5534/wjmh.2014.32.3.159.
Seo, W. I., Kang, P. M., Kim, T. H., Moon, K. H., Chung, J. M., Lee, D. H., Kim, I. Y., Min, K., Chung, J., Kim, W., & Kang, D. I. (2014). Primary androgen deprivation therapy for prostate cancer in koreans: a retrospective multicenter study. The world journal of men's health, 32(3), 159-66. https://doi.org/10.5534/wjmh.2014.32.3.159
Seo, Won Ik, et al. "Primary androgen deprivation therapy for prostate cancer in koreans: a retrospective multicenter study." The world journal of men's health vol. 32,3 (2014): 159-66. doi: https://doi.org/10.5534/wjmh.2014.32.3.159
Seo WI, Kang PM, Kim TH, Moon KH, Chung JM, Lee DH, Kim IY, Min K, Chung J, Kim W, Kang DI. Primary androgen deprivation therapy for prostate cancer in koreans: a retrospective multicenter study. World J Mens Health. 2014 Dec;32(3):159-66. doi: 10.5534/wjmh.2014.32.3.159. Epub 2014 Dec 29. PMID: 25606565; PMCID: PMC4298819.
Copy Download .nbib Format: NLM
Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients.

European urology focus

Klotz L, Grudén S, Axén N, Gauffin C, Wassberg C, Bjartell A, Giddens J, Incze P, Jansz K, Jievaltas M, Rendon R, Richard PO, Ulys A, Tammela TL.
PMID: 33583762
Eur Urol Focus. 2021 Feb 12; doi: 10.1016/j.euf.2021.02.003. Epub 2021 Feb 12.

BACKGROUND: There is increasing interest in nonmorbid treatments for low- and intermediate-risk prostate cancer with fewer side effects than surgery or radiotherapy.OBJECTIVE: To investigate the tolerability, safety, and antitumor effects of the intraprostatic NanoZolid depot formulation Liproca Depot (LIDDS...

Cite
Klotz L, Grudén S, Axén N, et al. Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients. Eur Urol Focus. 2021;doi: 10.1016/j.euf.2021.02.003.
Klotz, L., Grudén, S., Axén, N., Gauffin, C., Wassberg, C., Bjartell, A., Giddens, J., Incze, P., Jansz, K., Jievaltas, M., Rendon, R., Richard, P. O., Ulys, A., & Tammela, T. L. (2021). Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients. European urology focus, . https://doi.org/10.1016/j.euf.2021.02.003
Klotz, Laurence, et al. "Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients." European urology focus vol. (2021). doi: https://doi.org/10.1016/j.euf.2021.02.003
Klotz L, Grudén S, Axén N, Gauffin C, Wassberg C, Bjartell A, Giddens J, Incze P, Jansz K, Jievaltas M, Rendon R, Richard PO, Ulys A, Tammela TL. Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients. Eur Urol Focus. 2021 Feb 12; doi: 10.1016/j.euf.2021.02.003. Epub 2021 Feb 12. PMID: 33583762.
Copy Download .nbib Format: NLM
The Relationships between Survivals and Early Salvage Androgen Deprivation Therapy for Non-Organ Confined Prostate Cancer after Radical Prostatectomy.

Chonnam medical journal

Park JW, Choi YD.
PMID: 32509558
Chonnam Med J. 2020 May;56(2):115-120. doi: 10.4068/cmj.2020.56.2.115. Epub 2020 May 25.

Androgen deprivation therapy (ADT) is one salvage treatment used when prostate-specific antigen (PSA) recurs after radical prostatectomy (RP), especially in high-risk prostate cancer (PC) patients. However, the optimal timing for salvage ADT (SADT) is still unclear. In this study,...

Cite
Park JW, Choi YD. The Relationships between Survivals and Early Salvage Androgen Deprivation Therapy for Non-Organ Confined Prostate Cancer after Radical Prostatectomy. Chonnam Med J. 2020;56(2):115-120doi: 10.4068/cmj.2020.56.2.115.
Park, J. W., & Choi, Y. D. (2020). The Relationships between Survivals and Early Salvage Androgen Deprivation Therapy for Non-Organ Confined Prostate Cancer after Radical Prostatectomy. Chonnam medical journal, 56(2), 115-120. https://doi.org/10.4068/cmj.2020.56.2.115
Park, Jae Won, and Choi, Young Deuk. "The Relationships between Survivals and Early Salvage Androgen Deprivation Therapy for Non-Organ Confined Prostate Cancer after Radical Prostatectomy." Chonnam medical journal vol. 56,2 (2020): 115-120. doi: https://doi.org/10.4068/cmj.2020.56.2.115
Park JW, Choi YD. The Relationships between Survivals and Early Salvage Androgen Deprivation Therapy for Non-Organ Confined Prostate Cancer after Radical Prostatectomy. Chonnam Med J. 2020 May;56(2):115-120. doi: 10.4068/cmj.2020.56.2.115. Epub 2020 May 25. PMID: 32509558; PMCID: PMC7250674.
Copy Download .nbib Format: NLM
Roles of prohibitin in growth control and tumor suppression in human cancers.

Translational oncogenomics

Wang S, Faller DV.
PMID: 21566741
Transl Oncogenomics. 2008 Feb 10;3:23-37.

Tumor formation results from alterations in the normal control of cell proliferation. In the past decade, much attention in cancer research has been focused on the function of proto-oncogenes and tumor suppressors. Prohibitin is a potential tumor suppressor which...

Cite
Wang S, Faller DV. Roles of prohibitin in growth control and tumor suppression in human cancers. Transl Oncogenomics. 2008;3:23-37
Wang, S., & Faller, D. V. (2008). Roles of prohibitin in growth control and tumor suppression in human cancers. Translational oncogenomics, 323-37.
Wang, Sheng, and Faller, Douglas V. "Roles of prohibitin in growth control and tumor suppression in human cancers." Translational oncogenomics vol. 3 (2008): 23-37.
Wang S, Faller DV. Roles of prohibitin in growth control and tumor suppression in human cancers. Transl Oncogenomics. 2008 Feb 10;3:23-37. PMID: 21566741; PMCID: PMC3022352.
Copy Download .nbib Format: NLM
Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade.

Korean journal of urology

Choi JI, Kim YB, Yang SO, Lee JK, Jung TY.
PMID: 21860766
Korean J Urol. 2011 Jul;52(7):461-5. doi: 10.4111/kju.2011.52.7.461. Epub 2011 Jul 24.

PURPOSE: We evaluated the effectiveness of second-line maximum androgen blockade (MAB) with an alternative antiandrogen in patients who relapsed after initial MAB.MATERIALS AND METHODS: We retrospectively analyzed 47 patients with prostate cancer who relapsed after initial MAB, including surgical...

Cite
Choi JI, Kim YB, Yang SO, et al. Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade. Korean J Urol. 2011;52(7):461-5doi: 10.4111/kju.2011.52.7.461.
Choi, J. I., Kim, Y. B., Yang, S. O., Lee, J. K., & Jung, T. Y. (2011). Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade. Korean journal of urology, 52(7), 461-5. https://doi.org/10.4111/kju.2011.52.7.461
Choi, Joon Il, et al. "Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade." Korean journal of urology vol. 52,7 (2011): 461-5. doi: https://doi.org/10.4111/kju.2011.52.7.461
Choi JI, Kim YB, Yang SO, Lee JK, Jung TY. Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade. Korean J Urol. 2011 Jul;52(7):461-5. doi: 10.4111/kju.2011.52.7.461. Epub 2011 Jul 24. PMID: 21860766; PMCID: PMC3151633.
Copy Download .nbib Format: NLM
Androgen deprivation therapy and cardiovascular risk.

Nephro-urology monthly

Mourmouris P, Efstathiou E, Papatsoris A.
PMID: 23577326
Nephrourol Mon. 2013;5(1):653-4. doi: 10.5812/numonthly.7597. Epub 2012 Dec 15.

No abstract available.

Cite
Mourmouris P, Efstathiou E, Papatsoris A. Androgen deprivation therapy and cardiovascular risk. Nephrourol Mon. 2012;5(1):653-4doi: 10.5812/numonthly.7597.
Mourmouris, P., Efstathiou, E., & Papatsoris, A. (2013). Androgen deprivation therapy and cardiovascular risk. Nephro-urology monthly, 5(1), 653-4. https://doi.org/10.5812/numonthly.7597
Mourmouris, Panagiotis, et al. "Androgen deprivation therapy and cardiovascular risk." Nephro-urology monthly vol. 5,1 (2013): 653-4. doi: https://doi.org/10.5812/numonthly.7597
Mourmouris P, Efstathiou E, Papatsoris A. Androgen deprivation therapy and cardiovascular risk. Nephrourol Mon. 2013;5(1):653-4. doi: 10.5812/numonthly.7597. Epub 2012 Dec 15. PMID: 23577326; PMCID: PMC3614327.
Copy Download .nbib Format: NLM
Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival.

Cancers

Mansouri H, Alcaraz LB, Mollevi C, Mallavialle A, Jacot W, Boissière-Michot F, Simony-Lafontaine J, Laurent-Matha V, Roger P, Liaudet-Coopman E, Guiu S.
PMID: 32429078
Cancers (Basel). 2020 May 15;12(5). doi: 10.3390/cancers12051244.

BACKGROUND: In the triple-negative breast cancer (TNBC) group, the luminal androgen receptor subtype is characterized by expression of androgen receptor (AR) and lack of estrogen receptor and cytokeratin 5/6 expression. Cathepsin D (Cath-D) is overproduced and hypersecreted by breast...

Cite
Mansouri H, Alcaraz LB, Mollevi C, et al. Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival. Cancers (Basel). 2020;12(5)doi: 10.3390/cancers12051244.
Mansouri, H., Alcaraz, L. B., Mollevi, C., Mallavialle, A., Jacot, W., Boissière-Michot, F., Simony-Lafontaine, J., Laurent-Matha, V., Roger, P., Liaudet-Coopman, E., & Guiu, S. (2020). Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival. Cancers, 12(5), . https://doi.org/10.3390/cancers12051244
Mansouri, Hanane, et al. "Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival." Cancers vol. 12,5 (2020). doi: https://doi.org/10.3390/cancers12051244
Mansouri H, Alcaraz LB, Mollevi C, Mallavialle A, Jacot W, Boissière-Michot F, Simony-Lafontaine J, Laurent-Matha V, Roger P, Liaudet-Coopman E, Guiu S. Co-Expression of Androgen Receptor and Cathepsin D Defines a Triple-Negative Breast Cancer Subgroup with Poorer Overall Survival. Cancers (Basel). 2020 May 15;12(5). doi: 10.3390/cancers12051244. PMID: 32429078; PMCID: PMC7281089.
Copy Download .nbib Format: NLM
Adjuvant Effect of IV Clodronate on the Delay of Bone Metastasis in High-Risk Prostate Cancer Patients: A Prospective Study.

Cancer research and treatment

Rodrigues P, Hering FO, Meller A.
PMID: 22247708
Cancer Res Treat. 2011 Dec;43(4):231-5. doi: 10.4143/crt.2011.43.4.231. Epub 2011 Dec 27.

PURPOSE: High-risk prostate cancer patients undergoing treatment often experience biochemical recurrence. The use of bisphosphonates as an adjuvant treatment delays skeletal events, yet whether or not bisphosphonates also delay metastastic development remains to be determined.MATERIALS AND METHODS: A total...

Cite
Rodrigues P, Hering FO, Meller A. Adjuvant Effect of IV Clodronate on the Delay of Bone Metastasis in High-Risk Prostate Cancer Patients: A Prospective Study. Cancer Res Treat. 2011;43(4):231-5doi: 10.4143/crt.2011.43.4.231.
Rodrigues, P., Hering, F. O., & Meller, A. (2011). Adjuvant Effect of IV Clodronate on the Delay of Bone Metastasis in High-Risk Prostate Cancer Patients: A Prospective Study. Cancer research and treatment, 43(4), 231-5. https://doi.org/10.4143/crt.2011.43.4.231
Rodrigues, Paulo, et al. "Adjuvant Effect of IV Clodronate on the Delay of Bone Metastasis in High-Risk Prostate Cancer Patients: A Prospective Study." Cancer research and treatment vol. 43,4 (2011): 231-5. doi: https://doi.org/10.4143/crt.2011.43.4.231
Rodrigues P, Hering FO, Meller A. Adjuvant Effect of IV Clodronate on the Delay of Bone Metastasis in High-Risk Prostate Cancer Patients: A Prospective Study. Cancer Res Treat. 2011 Dec;43(4):231-5. doi: 10.4143/crt.2011.43.4.231. Epub 2011 Dec 27. PMID: 22247708; PMCID: PMC3253865.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 26 entries